The company is strengthening development and manufacturing offerings, says Anil Kane, global head of technical and scientific affairs for Thermo Fisher’s pharma services.
The agreements cover late-stage clinical supply of a monoclonal antibody targeting lymphoma and a small-molecule inhibitor being developed for actinic keratosis.
The Charles City facility will add 140,000 liters of capacity, while the company’s Milan site expansion is expected to be completed in the second half of 2027.
The collaboration aims to develop an automated, scalable manufacturing platform for gene-modified blood stem cell therapies for sickle cell disease and beta-thalassemia.
The partnership gives SK pharmteco access to Prozomix’s library of more than 6,000 native biocatalysts to support complex active pharmaceutical ingredient synthesis.
Global tariffs and trade tensions will continue to pressure biopharmaceutical manufacturers, driving supply chain decisions and the economics of domestic production. However, ...
Learn how different temperature monitoring tools reveal what your pharmaceutical shipments experienced and how to choose the right one to protect your supply chain.
Innovators are redefining bioreactor technology, cell and gene therapy manufacturing, pharmaceutical packaging, and small molecule APIs. Pharma Manufacturing’s 2025 Innovation...
Faced with increasing quality, risk, and talent pressures, pharma manufacturers are embracing smart manufacturing and automation to overcome these challenges. Find out in this...
Big Pharma and contract development and manufacturing organizations are making large capital expenditures to build infrastructure supporting the wildly popular medications.
Industrializing the manufacturing of these complex therapies is critical to ensure scalability and commercial viability, says the Alliance for Regenerative Medicine.
Large pharmaceutical companies have promised to invest more than $370 billion over the next five years in the U.S., driven by Trump’s threat of pharma-specific tariffs.
To counter the Chinese government’s investment, the U.S. must make a coordinated effort to grow biomanufacturing base, argues a bipartisan commission created by Congress.
The pharma giant has added to its inventory of orforglipron in anticipation of a favorable regulatory decision by the U.S. Food and Drug Administration.
Raleigh-Cary and Durham-Chapel Hill secured the first and third spots, respectively, as the nation’s most competitive markets for the production of therapeutic biologics.
SymphonX, which runs all downstream unit operations in both fed-batch and continuous processes, will serve customers at Fujifilm’s Billingham manufacturing facility.
These therapies are poised to reshape treatment standards this year, from next‑gen metabolic drugs to breakthrough advances in oncology, immunology, and rare diseases.
Home to pharma giants Roche and Novartis, the Swiss city along the Rhine River is attracting biotech companies of all sizes that are driving life sciences innovation.
As artificial intelligence tools proliferate, the real challenge is not generating ideas but turning them into chemically feasible and manufacturable paths.
Manufacturers face growing pressure to align drug design, production strategy, logistics, and workforce planning to ensure reliable, at-scale delivery.
Software platforms can seamlessly integrate with emerging technologies to unlock efficiencies, strengthen sustainability and enable proactive prevention of disruptions.
Built-in ability to meet data integrity standards should be a central focus when selecting control systems and manufacturing execution systems for pharma manufacturing
The agency cited the CDMO’s significant violations of current Good Manufacturing Practice regulations for finished pharmaceuticals at Simtra’s Halle/Westfalen facility.
The agency issued a Complete Response Letter for Incyte’s supplemental Biologics License Application, citing inspection findings at Novo Nordisk’s fill-finish facility.
Despite the legal setback for President Trump’s country-specific tariffs, he retains the authority to impose Section 232 tariffs on pharmaceuticals imported to the U.S.
Chinese production of active pharmaceutical ingredients and key starting materials is putting Americans at risk, according to a bipartisan congressional committee.
Production is highly concentrated globally making lower- and middle-income regions vulnerable to supply shocks, regulatory bottlenecks, and slow pandemic response.
Atradius and GlobalData see Britain as having a competitive advantage in attracting pharmaceutical production, thanks to tariff exemptions for drug exports to U.S.
Biomanufacturing scaling and supply chain resilience are top priorities for biopharma companies as they look to mitigate risks and capitalize on growth opportunities.
